While this still hasn’t been ‘SVR proven’, the preliminary 5 log-10 reduction at 14 days looks very interesting; more in the article from the hivandhepatitis site:
“SUMMARY: Results from the INFORM-1 trial, which evaluated 2 experimental agents that target different steps of the hepatitis C virus (HCV) lifecycle, showed that a combination of direct-acting drugs can suppress viral replication without interferon or ribavirin. As described in the October 14, 2010 advance online edition of The Lancet, the HCV protease inhibitor danoprevir (RG7227 or ITMN-191) plus the polymerase inhibitor RG7128 reduced HCV RNA by about 5 logs in both treatment-naive and previously treated patients, and caused no serious side effects in this 14-day study.”
http://www.hivandhepatitis.com/hep_c/news/2010/1022_2010_a.html
--Bill